Sabra Health Care REIT, Inc. (SBRA) Stock Analysis

Q: What is the SBRA stock price target?

Take-profit $20.34 (+1.0% upside). Target $20.34 (+1.1%), stop $19.28 (−4.3%), A.R:R -1.0:1.

Q: Is SBRA overvalued or undervalued?

Sabra Health Care REIT, Inc. trades at a P/E of 31.8 (forward 26.2). TrendMatrix value score: 4.4/10. Overall verdict: Hold.

Q: What do analysts say about SBRA?

20 analysts cover SBRA with a consensus score of 3.8/5. Average price target: $22.

Range Bound setup

HoldModerate ConfidenceUpdated 2026-04-30

Real Estate · REIT - Healthcare Facilities

Hold if already holding. Not a fresh buy at $20.11, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.4% away).

Sabra Health Care REIT invests in healthcare real estate in the US and Canada, leasing properties to skilled nursing, senior housing, behavioral health, and hospital operators. Revenue is primarily generated through lease payments and managed senior housing community operations.

$20.11+1.0% A.UpsideScore 5.7/10#4 of 13 REIT - Healthcare Facilities

Stop $19.28Target $20.34(resistance)A.R:R -1.0:1

Analyst target$22.00+9.4%13 analysts

$20.34our TP

$20.11price

$22.00mean

$24

Hold if already holding. Not a fresh buy at $20.11, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.4% away). Chart setup: RSI 45 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.

Passes 4/6 gates (clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.

Thesis

Rewards

High-quality business

Risks

Analyst target reached - limited upside remaining

Near 52-week high (4.4% away)

Negative momentum

Key Metrics

P/E (TTM)31.8

P/E (Fwd)26.2

Mkt Cap$5.1B

EV/EBITDA17.0

Profit Mgn20.1%

ROE5.6%

Rev Growth15.8%

Beta0.65

Dividend5.90%

Rating analysts20

Quality Signals

Piotroski F8/9

Options Flow

P/C0.43bullish

IV65%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value4.415%0.66

Quality7.215%1.08

Growth6.415%0.96

Momentum2.910%0.29

Sentiment6.510%0.65

Insider Activity5.010%0.50

Peer Rank5.510%0.55

Technical Setup6.15%0.30

Risk Profile5.25%0.26

Catalyst8.15%0.41

Overall (Σ contributions)5.66

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume

0.0

Obv

1.0

Macd

3.9

Ma Position

4.0

Rsi

5.5

Volume distribution (falling OBV)Above 200-day MA

GatesMomentum 2.9<4.5A.R:R -1.0=NEGATIVEInsider activity: OKNo SEC red flagsEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARRange BoundSuitability: Moderate

RSI

45 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $19.43Resistance $20.76

Price Targets

$19

$20

A.Upside+1.1%

A.R:R-1.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeCautious

Risk Alerts

! Target reached (-4.9% upside)

! Momentum score 2.9/10 — below 4.5 minimum

! Negative risk/reward — downside exceeds upside

Earnings

1/4 beats

Next Earnings2026-04-29 (nulld)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is SBRA stock a buy right now?

Hold if already holding. Not a fresh buy at $20.11, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.4% away). Chart setup: RSI 45 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $20.34 (+1.1%), stop $19.28 (−4.3%), A.R:R -1.0:1. Score 5.7/10, moderate confidence.

What is the SBRA stock price target?

Take-profit target: $20.34 (+1.0% upside). Target $20.34 (+1.1%), stop $19.28 (−4.3%), A.R:R -1.0:1. Stop-loss: $19.28.

What are the risks of investing in SBRA?

Analyst target reached - limited upside remaining; Near 52-week high (4.4% away); Negative momentum.

Is SBRA overvalued or undervalued?

Sabra Health Care REIT, Inc. trades at a P/E of 31.8 (forward 26.2). TrendMatrix value score: 4.4/10. Verdict: Hold.

What do analysts say about SBRA?

20 analysts cover SBRA with a consensus score of 3.8/5. Average price target: $22.

What does Sabra Health Care REIT, Inc. do?Sabra Health Care REIT invests in healthcare real estate in the US and Canada, leasing properties to skilled nursing,...